Loading...
Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management
Although breast cancer is a heterogeneous disease, approximately 20% to 25% of patients diagnosed with breast cancer have amplification of the HER2 gene. The FDA approval of trastuzumab for the treatment of HER2-positive (HER2+) metastatic breast cancer in 1998 represented a major breakthrough for p...
Saved in:
| Published in: | J Adv Pract Oncol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Harborside Press
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6750923/ https://ncbi.nlm.nih.gov/pubmed/31538025 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|